Berger, A. K., Haag, G. M., Grüllich, C., Dietrich, M., Apostolidis, L., Giesel, F. L., . . . Jäger, D. (2018). Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: Results of the phase II REMOTUX trial. British journal of cancer, 119(2), . https://doi.org/10.1038/s41416-018-0152-4
Chicago-Zitierstil (17. Ausg.)Berger, Anne Katrin, Georg Martin Haag, Carsten Grüllich, Mareike Dietrich, Leonidas Apostolidis, Frederik L. Giesel, Tim Weber, Uwe Haberkorn, und Dirk Jäger. "Early Metabolic Response in Sequential FDG-PET/CT Under Cetuximab Is a Predictive Marker for Clinical Response in First-line Metastatic Colorectal Cancer Patients: Results of the Phase II REMOTUX Trial." British Journal of Cancer 119, no. 2 (2018). https://doi.org/10.1038/s41416-018-0152-4.
MLA-Zitierstil (9. Ausg.)Berger, Anne Katrin, et al. "Early Metabolic Response in Sequential FDG-PET/CT Under Cetuximab Is a Predictive Marker for Clinical Response in First-line Metastatic Colorectal Cancer Patients: Results of the Phase II REMOTUX Trial." British Journal of Cancer, vol. 119, no. 2, 2018, https://doi.org/10.1038/s41416-018-0152-4.